drugset / Trial / NCT03303053

Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism

NCT03303053

RandomizedParallel-groupOpen-labelTreatment

Summary

Hyperthyroidism is the second most common endocrine disorder in the world with Graves' disease being the commonest. Anti thyroid drugs including methimazole, carbimazole, and propylthiouracil are effective treatments but take in most cases between 6 to 8 weeks to achieve euthyroidism. This study aim to assess the efficacy of cholestyramine and prednisolone as adjunctive treatment to standard treatment in patients with overt hyperthyroidism in 4 weeks.

Timeline

Start
2017-05-11
Primary completion
2018-03-01
Completion
2018-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholestyramine Other / unclassified 4 g
Subject Prednisolone Other / unclassified 5 mg
Comparator Carbimazole Small molecule 30 mg
Comparator Propranolol Small molecule 40 mg

Indications